ABSTRACT
Purpose
The present study aimed to develop novel glucagon-loaded PLGA nanospheres without cytotoxic fibril formation for chronic glucagon replacement therapy.
Methods
Glucagon-loaded nanospheres (GLG/NS) were prepared by an emulsion solvent diffusion method in oil, and a respirable powder formulation (GLG/NS-RP) was prepared with a jet mill. Physicochemical and inhalation properties of GLG/NS-RP were characterized, and pharmacokinetic behavior and hyperglycemic effect of intratracheally instilled GLG/NS-RP were evaluated in rats.
Results
Although preparation of GLG/NS using glucagon solution at concentrations over 10 mg/mL led to significant formation of cytotoxic glucagon aggregates, glucagon solution at less than 5 mg/mL did not cause structural changes. Drug release behavior of GLG/NS showed a biphasic pattern with an initial burst and slow diffusion. Laser diffraction and cascade impactor analyses of GLG/NS-RP suggested high dispersion and deposition in the respiratory organs with a fine particle fraction of 20.5%. After the intratracheal administration of the GLG/NS-RP (200 μg glucagon/kg) in rats, glucagon was released in a sustained manner, leading to sustained hyperglycemic effects compared with those of normal glucagon powder.
Conclusion
These data would suggest a therapeutic benefit of the newly developed GLG/NS-RP as an alternative to the injection form of glucagon currently used.
Similar content being viewed by others
REFERENCES
Unger RH, Dobbs RE, Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol. 1978;40:307–43.
Mochiki E, Suzuki H, Takenoshita S, Nagamachi Y, Kuwano H, Mizumoto A, et al. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J Gastroenterol. 1998;33:835–41.
Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25:452–60.
Hirota M, Ikei S, Mishima M, Mori K, Sakamoto K, Yamane T, et al. Glucagon in the metabolic and nutritional management after total pancreatectomy–a case report. Jpn J Surg. 1989;19:586–92.
Teshima D, Yamauchi A, Makino K, Kataoka Y, Arita Y, Nawata H, et al. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm. 2002;233:61–6.
Endo K, Amikawa S, Matsumoto A, Sahashi N, Onoue S. Erythritol-based dry powder of glucagon for pulmonary administration. Int J Pharm. 2005;290:63–71.
Onoue S, Yamamoto K, Kawabata Y, Hirose M, Mizumoto T, Yamada S. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery. Int J Pharm. 2009;382:144–50.
Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28:43–70.
Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci. 2008;97:2395–404.
Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21:1274–83.
Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science. 2009;325:328–32.
Merrifield RB. Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol. 1969;32:221–96.
Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm. 1998;45:41–8.
Onoue S, Waki Y, Nagano Y, Satoh S, Kashimoto K. The neuromodulatory effects of VIP/PACAP on PC-12 cells are associated with their N-terminal structures. Peptides. 2001;22:867–72.
LeVine 3rd H. Thioflavine T interaction with synthetic Alzheimer’s disease beta- amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404–10.
Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Isshiki N, Momose D, et al. Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler by polymorphic transformation to needle-like crystals (beta-form). Pharm Res. 2002;19:1439–45.
Onoue S, Yajima T. Fibrillar aggregates of amyloidogenic peptides: new Insight into the neuroprotective effects of neuropeptides on fibril-induced neuronal cell death. NY: Nova Science Publishers; 2006.
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507–11.
Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325:172–9.
Zheng XM, Martin GP, Marriott C. Particulate interactions in dry powder formulations for inhalation. London: Taylor&Francis; 2001.
Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm. 2003;257:283–96.
Maeda H, Okabayashi T, Yatabe T, Yamashita K, Hanazaki K. Perioperative intensive insulin therapy using artificial endocrine pancreas in patients undergoing pancreatectomy. World J Gastroenterol. 2009;15:4111–5.
Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005;7:E20–41.
Patton JS. Pulmonary delivery of drugs for bone disorders. Adv Drug Deliv Rev. 2000;42:239–48.
Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2:198–209.
Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia. 2000;43:1012–9.
ACKNOWLEDGMENTS
This work was supported in part by a Grant-in-Aid for Young Scientists (B) (No.22790043; S. Onoue) from the Ministry of Education, Culture, Sports, Science and Technology, and Project of Shizuoka Prefecture and Shizuoka City Collaboration of Regional Entities for the Advancement of Technological Excellence, Japan Science and Technology Agency (JST).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onoue, S., Kuriyama, K., Uchida, A. et al. Inhalable Sustained-Release Formulation of Glucagon: In Vitro Amyloidogenic and Inhalation Properties, and In Vivo Absorption and Bioactivity. Pharm Res 28, 1157–1166 (2011). https://doi.org/10.1007/s11095-011-0379-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-011-0379-8